| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S11938-016-0111-1 |
| P698 | PubMed publication ID | 27699625 |
| P2093 | author name string | Ron Schey | |
| Zachary Wilmer Reichenbach | |||
| P2860 | cites work | Cannabis for Inflammatory Bowel Disease | Q22241934 |
| The neurobiology and evolution of cannabinoid signalling | Q24522320 | ||
| Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation | Q24643922 | ||
| The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 | ||
| Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew | Q46514836 | ||
| Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors | Q46584481 | ||
| Fatty acid amide hydrolase controls mouse intestinal motility in vivo | Q46687826 | ||
| The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells | Q46875092 | ||
| Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation. | Q47829257 | ||
| Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial | Q48065211 | ||
| Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret | Q48188856 | ||
| Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. | Q48191169 | ||
| Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study | Q48223585 | ||
| Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. | Q51491977 | ||
| Involvement of the transient receptor potential vanilloid 1 (TRPV1) in the development of acute visceral hyperalgesia during colorectal distension in rats. | Q51736427 | ||
| Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. | Q52001605 | ||
| GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. | Q52023779 | ||
| Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. | Q53469661 | ||
| Association of cannabinoid type 1 receptor and fatty acid amide hydrolase genetic polymorphisms in Chinese patients with irritable bowel syndrome. | Q54227125 | ||
| Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats | Q60690593 | ||
| Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice | Q60690689 | ||
| Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system | Q73193706 | ||
| Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor | Q73571526 | ||
| Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes | Q77341707 | ||
| Physiology of microglial cells | Q81683764 | ||
| Cannabinoids in microglia: a new trick for immune surveillance and neuroprotection | Q82143222 | ||
| Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium | Q83019190 | ||
| Molecular biology of cannabinoid receptors | Q83096667 | ||
| The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients | Q84760172 | ||
| The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt | Q95716793 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons | Q28144567 | ||
| Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway | Q28215554 | ||
| Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome | Q28244460 | ||
| Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 | Q28270721 | ||
| Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats | Q28271665 | ||
| Cannabinoids and the gut: new developments and emerging concepts | Q28271862 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study | Q28290187 | ||
| The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome | Q28291178 | ||
| Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system | Q28301264 | ||
| Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation | Q28361058 | ||
| Cannabinoids and the gastrointestinal tract | Q28365382 | ||
| The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats | Q28378072 | ||
| Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats | Q28568772 | ||
| Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain | Q30047898 | ||
| Cannabinoid receptor signaling. | Q30353713 | ||
| CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice | Q30499515 | ||
| Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. | Q33918606 | ||
| Cannabinoid receptors and the regulation of immune response | Q34099012 | ||
| Cannabinoids for gastrointestinal diseases: potential therapeutic applications | Q34169100 | ||
| Cannabinoid hyperemesis syndrome | Q34239091 | ||
| A new strategy to block tumor growth by inhibiting endocannabinoid inactivation | Q34338108 | ||
| Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting | Q34381296 | ||
| Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. | Q34399907 | ||
| Evidence for novel cannabinoid receptors | Q34415409 | ||
| The role of cannabinoids in regulation of nausea and vomiting, and visceral pain | Q34464535 | ||
| Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. | Q34524930 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Cannabinoid receptors and their ligands | Q34673022 | ||
| Molecular biology of cannabinoid receptors | Q34673034 | ||
| Endocannabinoids and the gut. | Q34673219 | ||
| Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity | Q34749518 | ||
| The epidemiology of irritable bowel syndrome in North America: a systematic review | Q34791832 | ||
| CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling | Q35035833 | ||
| Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors | Q35213727 | ||
| Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis | Q35214374 | ||
| The therapeutic potential of orphan GPCRs, GPR35 and GPR55. | Q35425244 | ||
| AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner | Q35484505 | ||
| Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. | Q35693020 | ||
| Involvement of cannabinoid receptors in gut motility and visceral perception | Q35752224 | ||
| Endocannabinoids and the regulation of their levels in health and disease | Q36758111 | ||
| A potential role for GPR55 in gastrointestinal functions | Q36864469 | ||
| Genetic polymorphisms of the endocannabinoid system | Q36916150 | ||
| In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. | Q37032490 | ||
| Targeting the endocannabinoid system: to enhance or reduce? | Q37150745 | ||
| Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception | Q37162136 | ||
| Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis | Q37215363 | ||
| Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans | Q37230841 | ||
| Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids | Q37337693 | ||
| The endogenous cannabinoid system protects against colonic inflammation | Q37370275 | ||
| Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception | Q37394887 | ||
| Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells | Q37599138 | ||
| Neuroprotective agents: cannabinoids | Q37855122 | ||
| Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury. | Q37862329 | ||
| Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. | Q37960078 | ||
| The gastrointestinal pharmacology of cannabinoids: focus on motility | Q38018818 | ||
| Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher". | Q38196875 | ||
| Functional CB1 cannabinoid receptors in human vascular endothelial cells | Q38314869 | ||
| Endocannabinoid transport revisited. | Q38394132 | ||
| A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial | Q38405787 | ||
| GPR55 - a putative "type 3" cannabinoid receptor in inflammation | Q38669741 | ||
| Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice. | Q38893169 | ||
| Epidemiology and mechanisms of gastroesophageal reflux disease in the elderly: a perspective | Q38928066 | ||
| Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease | Q39213927 | ||
| Cannabinoid receptors CB1 and CB2 form functional heteromers in brain | Q39359086 | ||
| A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice | Q39432376 | ||
| Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide | Q39467487 | ||
| Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse | Q40196873 | ||
| Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses | Q40943005 | ||
| Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. | Q41292913 | ||
| Cannabinoid-receptor expression in human leukocytes | Q41553271 | ||
| The GPR55 antagonist CID16020046 protects against intestinal inflammation. | Q41638096 | ||
| Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). | Q42012570 | ||
| Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate | Q42034486 | ||
| Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting | Q42169489 | ||
| Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats | Q42501114 | ||
| Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. | Q43263874 | ||
| Abnormal anandamide metabolism in celiac disease. | Q43769821 | ||
| Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret | Q43770448 | ||
| The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids | Q43830097 | ||
| Effect of cannabinoids on neural transmission in rat gastric fundus | Q43929885 | ||
| Endocannabinoids as physiological regulators of colonic propulsion in mice | Q44054030 | ||
| Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus | Q44062680 | ||
| Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. | Q44165160 | ||
| Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 | ||
| Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats | Q44482025 | ||
| Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets | Q44524942 | ||
| CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents | Q45059343 | ||
| Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors | Q45153412 | ||
| The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice | Q46164977 | ||
| Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon | Q46228825 | ||
| P433 | issue | 4 | |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 461-477 | |
| P577 | publication date | 2016-10-03 | |
| P1433 | published in | Current treatment options in gastroenterology | Q27714745 |
| P1476 | title | Cannabinoids and GI Disorders: Endogenous and Exogenous | |
| P478 | volume | 14 |
| Q47839554 | Endocannabinoid-related compounds in gastrointestinal diseases. | cites work | P2860 |
Search more.